{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Veloxis+Pharmaceuticals",
    "query": {
      "sponsor": "Veloxis Pharmaceuticals",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 40,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Veloxis+Pharmaceuticals&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Veloxis+Pharmaceuticals&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T03:13:35.115Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00496483",
      "title": "Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "LCP Tacro (tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "Prograf",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-07",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2015-07-23",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496483"
    },
    {
      "nct_id": "NCT01187953",
      "title": "Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "Prograf (tacrolimus)",
          "type": "DRUG"
        },
        {
          "name": "LCP-Tacro",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 543,
      "start_date": "2010-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-05-18",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacremento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187953"
    },
    {
      "nct_id": "NCT03263052",
      "title": "Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Disorder Related to Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Tacrolimus XR (Envarsus)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2017-07-01",
      "completion_date": "2020-01-01",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03263052"
    },
    {
      "nct_id": "NCT04225988",
      "title": "Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "Extended-release tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Immediate-release tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-01-09",
      "completion_date": "2023-07-11",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225988"
    },
    {
      "nct_id": "NCT03979365",
      "title": "Envarsus XR Compared to Immediate Release Tacrolimus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Envarsus XR",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 261,
      "start_date": "2019-07-18",
      "completion_date": "2022-03-29",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03979365"
    },
    {
      "nct_id": "NCT03828682",
      "title": "Veloxis de Novo Kidney Transplant ECSWD",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplantation",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended Release Oral Tablet [Envarsus]",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolic Acid Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Simon Tremblay, PharmD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-06-21",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-05-13",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03828682"
    },
    {
      "nct_id": "NCT02339246",
      "title": "Pharmacokinetic Comparison Of All FK-506 Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "Prograf vs Envarsus XR vs Astagraf XL",
          "type": "DRUG"
        },
        {
          "name": "Prograf vs Astagraf XL vs Envarsus XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-18",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339246"
    },
    {
      "nct_id": "NCT03555448",
      "title": "Once Daily Immunosuppression Regimen",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Once daily immunosuppression regimen",
          "type": "DRUG"
        },
        {
          "name": "Twice daily immunosuppression regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2018-06-04",
      "completion_date": "2023-11-10",
      "has_results": true,
      "last_update_posted_date": "2025-01-22",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03555448"
    },
    {
      "nct_id": "NCT03461445",
      "title": "Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant; Complications",
        "Toxicity",
        "Drug Toxicity",
        "Neurotoxicity"
      ],
      "interventions": [
        {
          "name": "Envarsus",
          "type": "DRUG"
        },
        {
          "name": "IR Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-04-01",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03461445"
    },
    {
      "nct_id": "NCT00504829",
      "title": "Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "LCP-AtorFen",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "fenofibrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2007-07",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2020-02-17",
      "last_synced_at": "2026-10-11T03:13:35.115Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504829"
    }
  ]
}